NME8 Antibody

What is NME8 and why is it an important research target?

NME8 (NME/NM23 family member 8, also known as TXNDC3, SPTRX2, NM23-H8) is a protein with an N-terminal thioredoxin domain and three C-terminal nucleoside diphosphate kinase (NDPK) domains. It's an important research target because:

• It plays critical roles in cellular protection against oxidative stress and DNA damage

• It is highly expressed in testis and implicated in sperm development and function

• Mutations in NME8 are associated with primary ciliary dyskinesia type 6

• It demonstrates protective functions against chemotherapy-induced reproductive toxicity

The protein's dual functionality (antioxidant capacity through the thioredoxin domain and potential DNA repair through its 3'-5' exonuclease activity) makes it particularly interesting for reproductive biology and cancer research .

NME8 antibodies have been validated for several experimental applications:

• Immunohistochemistry (IHC): Successfully used for detecting NME8 in paraffin-embedded human tissues including lung cancer and colorectal cancer tissues. Recommended dilutions typically range from 1:100-1:200 .

• Western Blotting (WB): Effective for detecting the ~67 kDa NME8 protein in cell and tissue lysates. Recommended dilutions range from 1:500-1:2000 .

• ELISA: Some antibodies are validated for ELISA applications with dilutions ranging from 1:2000-1:10000 .

When selecting an antibody, researchers should consider the specific application needed and the species being studied, as reactivity varies between products .

How should I design validation experiments for NME8 antibodies in my specific research context?

Following the "five pillars" approach to antibody validation recommended by the International Working Group for Antibody Validation , consider:

• Genetic strategies: Use NME8 knockout models or knockdown approaches (siRNA/shRNA) as negative controls. Research has shown NME8 knockout mice are viable and can serve as excellent negative controls for antibody specificity testing .

• Orthogonal strategies: Compare antibody-based NME8 detection with non-antibody methods like mass spectrometry or mRNA expression analysis (RT-qPCR).

• Independent antibody validation: Compare results using multiple antibodies targeting different epitopes of NME8. Available antibodies target different regions including C-terminal epitopes .

• Expression validation: Overexpress NME8 in a model system using recombinant techniques to create a positive control.

• Immunoprecipitation-MS: Perform immunoprecipitation followed by mass spectrometry to confirm the antibody captures the intended target.

For tissues with expected high NME8 expression (like testis), include these as positive controls in your experiments .

What are the optimal protocols for detecting subcellular localization of NME8?

NME8 exhibits complex subcellular localization patterns that can change under different conditions:

• Standard conditions: NME8 is primarily localized in the cytoplasm of spermatocytes and in the principal piece of sperm .

• Stress conditions: Upon cisplatin treatment, NME8 can translocate to the nucleus, suggesting a potential role in DNA damage response .

For optimal subcellular localization studies:

• Immunofluorescence protocol:

  • Use fresh-frozen or PFA-fixed tissue sections (4% PFA, 10-15 minutes)

  • Permeabilize with 0.1-0.3% Triton X-100

  • Block with 5% normal serum

  • Incubate with NME8 antibody (1:100-1:200 dilution)

  • Use appropriate fluorophore-conjugated secondary antibody

  • Counterstain nuclei with DAPI

  • Analyze using confocal microscopy for optimal resolution

• Co-localization studies: Consider co-staining with markers for specific subcellular compartments to confirm localization patterns:

  • Nuclear markers (DAPI)

  • Sperm tail markers for studying localization in spermatozoa

  • Stress response markers when studying translocation under stress conditions

• Fractionation approach: Complement immunofluorescence with subcellular fractionation followed by Western blotting to biochemically verify localization patterns .

What controls should I include when using NME8 antibodies in IHC and Western blot applications?

For Immunohistochemistry:

• Positive tissue controls: Include tissues known to express NME8:

  • Testis tissue (high expression)

  • Lung cancer tissue (validated in previous studies)

  • Colorectal cancer tissue (validated in previous studies)

• Negative controls:

  • Primary antibody omission

  • Isotype control antibody at the same concentration

  • Tissue from NME8 knockout models if available

  • Pre-absorption with immunizing peptide/protein

• Dilution optimization: Test a range of antibody dilutions (e.g., 1:50, 1:100, 1:200, 1:500) to determine optimal signal-to-noise ratio .

For Western Blotting:

• Positive controls:

  • Testis tissue lysate (high expression)

  • Recombinant NME8 protein

  • Cells/tissues known to express NME8

• Negative controls:

  • Tissues from NME8 knockout models

  • Cells with NME8 knockdown

  • Tissues known not to express NME8

• Loading controls: Include appropriate loading controls (β-actin, GAPDH, etc.) to normalize protein loading

• Molecular weight verification: Confirm that the detected band appears at the expected molecular weight (~67 kDa) .

How can I investigate NME8's role in oxidative stress response and DNA damage repair?

NME8 contains a thioredoxin domain and demonstrates 3'-5' exonuclease activity, suggesting roles in both oxidative stress response and DNA repair . To investigate these functions:

Oxidative Stress Response Studies:

• ROS detection: Compare reactive oxygen species (ROS) levels between wild-type and NME8-deficient cells under normal and stress conditions using:

  • DCFDA (2',7'-dichlorofluorescin diacetate) fluorescence assay

  • MitoSOX Red for mitochondrial superoxide detection

• Antioxidant capacity assessment: Measure antioxidant enzyme activities in presence/absence of NME8:

  • Glutathione (GSH) levels

  • Superoxide dismutase (SOD) activity

  • Catalase activity

• Lipid peroxidation: Assess lipid peroxidation using:

  • Malondialdehyde (MDA) assay

  • 4-hydroxynonenal (4-HNE) immunostaining

Research has shown that NME8 deficiency further impairs antioxidant capacity, induces lipid peroxidation, and increases ROS levels under cisplatin treatment .

DNA Damage Response Studies:

• DNA damage markers: Compare markers between wild-type and NME8-deficient samples:

  • 8-OHdG (8-hydroxy-2 deoxyguanosine) levels for oxidative DNA damage

  • γH2AX immunostaining for double-strand breaks

  • TUNEL assay for DNA fragmentation

• Comet assay: Assess DNA strand breaks using alkaline or neutral comet assay

• DNA fragmentation in sperm: Use Sperm Chromatin Dispersion (SCD) assay to analyze DNA fragmentation patterns

• Nuclear translocation: Study NME8 translocation to nuclei under genotoxic stress using immunofluorescence and subcellular fractionation .

What approaches can be used to study NME8's involvement in autophagy activation?

Recent research indicates NME8 plays a role in autophagy activation, particularly under stress conditions . To investigate this function:

• Autophagy markers: Compare autophagy markers between wild-type and NME8-deficient samples:

  • LC3-I to LC3-II conversion (Western blot)

  • p62/SQSTM1 degradation (Western blot)

  • Beclin-1 levels (Western blot or IHC)

  • ATG5-ATG12 complex formation

• Autophagosome visualization:

  • Transmission electron microscopy to visualize autophagosomes

  • Immunofluorescence for LC3 puncta formation

  • GFP-LC3 reporter systems in cell models

• Autophagy flux assessment:

  • Perform studies with and without autophagy inhibitors (Bafilomycin A1, Chloroquine)

  • Compare LC3-II accumulation under these conditions

• Pathway analysis:

  • Investigate mTOR pathway activation status (phospho-mTOR, p70S6K, 4E-BP1)

  • AMPK pathway activation (phospho-AMPK)

  • ULK1 phosphorylation status

• Rescue experiments:

  • Attempt to rescue autophagy defects in NME8-deficient cells by:

    • NME8 re-expression

    • Chemical autophagy inducers (rapamycin, etc.)

    • Expression of autophagy pathway components

Research has shown that NME8 deficiency results in failure to activate autophagy under cisplatin treatment, suggesting a critical role for NME8 in stress-induced autophagy activation .

How can I explore potential compensatory mechanisms between NME8 and other NME family members?

Studies with NME8 knockout mice showed normal fertility, suggesting possible functional compensation by other NME family members, particularly NME5 . To investigate compensatory mechanisms:

• Expression analysis:

  • Assess changes in expression of other NME family members in NME8-deficient models using:

    • RT-qPCR for mRNA levels

    • Western blot for protein levels

    • Immunohistochemistry for tissue localization patterns

  • Focus particularly on NME5, which has been suggested as a compensatory protein

• Double knockdown/knockout approaches:

  • Generate NME5/NME8 double knockout models or use combinatorial knockdown

  • Administer NME5 knockdown adenovirus into NME8 knockout mice to test the compensatory hypothesis

  • Assess phenotypic changes compared to single knockouts

• Domain function analysis:

  • Compare functional domains between NME family members

  • Since NME5 only contains NDPK domains and lacks the thioredoxin domain found in NME8, investigate whether:

    • NDPK domains are sufficient for spermatogenesis

    • The thioredoxin domain becomes essential under stress conditions

• Rescue experiments:

  • Overexpress NME5 in NME8-deficient cells under stress conditions

  • Test whether NME5 overexpression can rescue phenotypes observed in NME8-deficient cells treated with cisplatin

• Protein interaction studies:

  • Perform co-immunoprecipitation studies to identify interaction partners of NME8

  • Compare with interaction partners of other NME family members

  • Identify shared pathways that might explain functional redundancy

Why might I observe variable or inconsistent staining patterns with NME8 antibodies in IHC applications?

Several factors can contribute to variable or inconsistent staining with NME8 antibodies:

• Tissue processing variables:

  • Fixation time and conditions (over/under-fixation)

  • Antigen retrieval methods (citrate vs. EDTA buffer, pH variations)

  • Section thickness (optimal is typically 4-5 μm)

• Antibody-specific factors:

  • Different epitope recognition between antibody lots

  • Polyclonal antibodies may have batch-to-batch variations

  • Storage conditions affecting antibody stability

• Biological variables:

  • NME8 expression levels vary significantly between tissues

  • Subcellular localization can change under stress conditions (cytoplasmic vs. nuclear)

  • Post-translational modifications may affect epitope accessibility

• Technical considerations:

  • Detection system sensitivity (DAB vs. fluorescent detection)

  • Signal amplification methods

  • Non-specific binding to similar epitopes

To address these issues:

• Optimize antigen retrieval conditions for your specific tissue type

• Test multiple antibody dilutions and incubation times

• Consider using different NME8 antibodies targeting distinct epitopes

• Include appropriate positive and negative controls in each experiment

• Document the exact conditions used for reproducibility

How should I interpret apparent discrepancies between NME8 expression detected by antibody-based methods versus mRNA expression?

Discrepancies between protein and mRNA expression levels are common in biological systems and may reflect important regulatory mechanisms. When interpreting such discrepancies for NME8:

• Post-transcriptional regulation:

  • mRNA stability and degradation rates

  • microRNA-mediated regulation

  • Alternative splicing events (particularly relevant as NME8 has multiple splice variants)

• Post-translational regulation:

  • Protein stability differences

  • Protein degradation rates (proteasomal or autophagy-mediated)

  • Subcellular localization changes affecting detection

• Technical considerations:

  • Different sensitivities between RT-qPCR and antibody-based detection

  • Epitope masking due to protein interactions or conformational changes

  • Antibody specificity issues detecting all protein isoforms

• Biological timing:

  • Temporal delay between transcription and translation

  • Differential regulation under stress conditions

Methodological approaches to reconcile discrepancies:

• Perform time-course studies to capture dynamic regulation

• Use multiple antibodies targeting different epitopes

• Employ orthogonal protein detection methods (mass spectrometry)

• Investigate protein stability using proteasome inhibitors

• Examine splice variants using isoform-specific primers for RT-qPCR

What are the critical considerations when using NME8 antibodies to study stress-induced translocation?

Research has shown that NME8 can translocate from the cytoplasm to the nucleus under cisplatin-induced stress . When studying such translocation events:

• Experimental design considerations:

  • Establish appropriate time-course for observation (translocation may be transient)

  • Determine optimal stress conditions (concentration, duration)

  • Include appropriate controls for stress induction

• Technical considerations:

  • Use high-resolution imaging (confocal microscopy) for clear subcellular localization

  • Employ complementary approaches:

    • Immunofluorescence for visual confirmation

    • Subcellular fractionation followed by Western blotting for biochemical verification

    • Live-cell imaging with fluorescently tagged NME8 for dynamic studies

• Validation approaches:

  • Quantify nuclear/cytoplasmic fluorescence intensity ratios

  • Perform co-localization studies with nuclear markers

  • Block nuclear import/export mechanisms to confirm translocation mechanism

• Biological interpretation:

  • Correlate translocation with functional outcomes (DNA damage markers, cell survival)

  • Investigate potential post-translational modifications triggering translocation

  • Examine which domains of NME8 are required for nuclear localization

• Common pitfalls:

  • Fixation artifacts can affect apparent localization

  • Antibody cross-reactivity with other nuclear proteins

  • Overlooking heterogeneity in cellular responses

Research indicates that nuclear translocation of NME8 may be related to its 3'-5' exonuclease activity and potential role in DNA damage repair , making this an important aspect of functional studies.

What emerging technologies might enhance NME8 antibody development and validation?

Several cutting-edge technologies are poised to improve NME8 antibody development and validation:

• Recombinant antibody technologies:

  • Phage display selection of high-affinity binders

  • Yeast display platforms for antibody optimization

  • Single B-cell cloning approaches for monoclonal antibody development

  • Computational design of antibody binding regions

• Advanced validation technologies:

  • CRISPR-Cas9 knockout validation systems

  • Proximity labeling approaches (BioID, APEX) to confirm interaction partners

  • Single-molecule imaging techniques to track NME8 dynamics

  • Spatial proteomics for better localization studies

• Structural biology approaches:

  • Cryo-EM for antibody-antigen complex visualization

  • Hydrogen-deuterium exchange mass spectrometry for epitope mapping

  • AlphaFold2 predictions to guide antibody development against specific domains

• Machine learning applications:

  • Prediction of antibody-antigen binding through library-on-library approaches

  • Active learning strategies to reduce experimental burden in antibody development

  • Models that can predict out-of-distribution antibody-antigen interactions

These technologies could address current limitations by:

• Improving specificity through better epitope targeting

• Enhancing reproducibility through recombinant approaches

• Reducing cross-reactivity through computational design

• Accelerating validation through machine learning prediction

How might NME8 antibodies contribute to clinical applications based on current research findings?

Based on recent findings about NME8's functions, antibodies against this protein could contribute to several potential clinical applications:

• Cancer therapy adjuvants:

  • Monitoring NME8 expression in response to cisplatin treatment

  • Potential biomarker for treatment response in certain cancers

  • Development of strategies to enhance NME8's protective functions in non-cancer tissues during chemotherapy

• Reproductive medicine:

  • Diagnostic tools for primary ciliary dyskinesia and related fertility issues

  • Assessment of sperm quality and potential fertility issues

  • Monitoring NME8 expression/localization in fertility preservation strategies for cancer patients

• Biomarker development:

  • Potential diagnostic or prognostic marker for conditions involving oxidative stress

  • Indicator of DNA damage response activation

  • Marker for autophagy activation status in various pathological conditions

• Therapeutic development:

  • Target validation for strategies aiming to enhance cellular protection against chemotherapy

  • Development of mimetics that replicate NME8's protective functions

  • Screening tools for compounds that modulate NME8 activity or expression

Current limitations and research needs:

• Better understanding of NME8's tissue-specific functions beyond reproductive tissues

• Clarification of the relationship between NME8 mutations and disease phenotypes

• Development of standardized assays for clinical evaluation of NME8 status

What are the current gaps in understanding NME8's molecular functions that future antibody-based studies could address?

Despite recent advances, several knowledge gaps remain in understanding NME8's molecular functions that could be addressed through antibody-based approaches:

• Domain-specific functions:

  • Developing domain-specific antibodies to distinguish the roles of:

    • Thioredoxin domain in antioxidant functions

    • NDPK domains in potential enzymatic activities

    • 3'-5' exonuclease activity in DNA repair

  • Determining which domains are critical for different cellular functions

• Interaction partners:

  • Using antibodies for co-immunoprecipitation studies to identify:

    • Protein-protein interaction networks

    • Complexes formed under normal vs. stress conditions

    • Differential interactions in various cell types/tissues

• Post-translational modifications:

  • Developing modification-specific antibodies to detect:

    • Phosphorylation sites regulating translocation

    • Oxidation states of the thioredoxin domain

    • Ubiquitination patterns affecting protein stability

• Compensatory mechanisms:

  • Using antibodies to track expression changes in:

    • Other NME family members in NME8-deficient models

    • Related proteins involved in antioxidant defense

    • DNA repair pathway components

• Temporal dynamics:

  • Employing antibodies in time-course studies to understand:

    • Immediate vs. delayed responses to oxidative stress

    • Nuclear-cytoplasmic shuttling kinetics

    • Protein turnover rates under different conditions

Methodological approaches to address these gaps:

• Development of conditional knockout models for tissue-specific studies

• Super-resolution microscopy for detailed localization studies

• Proximity labeling combined with mass spectrometry

• Single-cell analyses to capture heterogeneity in responses

• Development of activity-based probes to monitor functional states